Mark S. Sulkowski, MD
Mark S. Sulkowski, MD
Professor of Medicine; Johns Hopkins University School of Medicine
Verified email at
Cited by
Cited by
Mandell, douglas, and bennett's principles and practice of infectious diseases: 2-volume set
JE Bennett, R Dolin, MJ Blaser
Elsevier Health Sciences, 2014
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
D Ge, J Fellay, AJ Thompson, JS Simon, KV Shianna, TJ Urban, ...
Nature 461 (7262), 399-401, 2009
Boceprevir for untreated chronic HCV genotype 1 infection
F Poordad, J McCone Jr, BR Bacon, S Bruno, MP Manns, MS Sulkowski, ...
New England Journal of Medicine 364 (13), 1195-1206, 2011
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Q Yang, TE Graham, N Mody, F Preitner, OD Peroni, JM Zabolotny, ...
Nature 436 (7049), 356-362, 2005
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
RK Sterling, E Lissen, N Clumeck, R Sola, MC Correa, J Montaner, ...
Hepatology 43 (6), 1317-1325, 2006
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
JG McHutchison, EJ Lawitz, ML Shiffman, AJ Muir, GW Galler, J McCone, ...
New England Journal of Medicine 361 (6), 580-593, 2009
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ...
New England Journal of Medicine 370 (16), 1483-1493, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ...
New England Journal of Medicine 370 (3), 211-221, 2014
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ...
New England Journal of Medicine 360 (18), 1827-1838, 2009
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ...
New England journal of medicine 368 (20), 1867-1877, 2013
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
MS Sulkowski, DL Thomas, RE Chaisson, RD Moore
JAMA: The Journal of the American Medical Association 283 (1), 74, 2000
Response-guided telaprevir combination treatment for hepatitis C virus infection
KE Sherman, SL Flamm, NH Afdhal, DR Nelson, MS Sulkowski, ...
New England Journal of Medicine 365 (11), 1014-1024, 2011
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and …
E Lawitz, MS Sulkowski, R Ghalib, M Rodriguez-Torres, ZM Younossi, ...
The Lancet 384 (9956), 1756-1765, 2014
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States
SH Mehta, FL Brancati, MS Sulkowski, SA Strathdee, M Szklo, DL Thomas
Annals of internal medicine 133 (8), 592-599, 2000
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, ...
Gastroenterology 139 (1), 120-129. e18, 2010
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ...
New England Journal of Medicine 373 (27), 2608-2617, 2015
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ...
Gastroenterology 149 (3), 649-659, 2015
Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin
S Zeuzem, IM Jacobson, T Baykal, RT Marinho, F Poordad, M Bourlière, ...
New England Journal of Medicine 370 (17), 1604-1614, 2014
Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: role of hepatitis C and B infections
MS Sulkowski, DL Thomas, SH Mehta, RE Chaisson, RD Moore
Hepatology 35 (1), 182-189, 2002
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
AASLD/IDSA HCV Guidance Panel, RT Chung, GL Davis, DM Jensen, ...
Hepatology 62 (3), 932-954, 2015
The system can't perform the operation now. Try again later.
Articles 1–20